How to Help Your Patients Save Money on Tresiba: A Provider's Guide to Savings Programs

You've prescribed Tresiba (insulin degludec) because it's the right clinical choice — ultra-long duration, flat pharmacokinetic profile, flexible dosing timing, and proven reduction in severe hypoglycemia. But none of that matters if your patient can't afford to fill the prescription.

Insulin affordability remains one of the most significant barriers to adherence in diabetes care. A 2023 CDC analysis found that roughly 1 in 4 insulin users reported cost-related rationing. The retail cost of Tresiba without insurance can exceed $400 per box of pens. Even with insurance, high copays and deductibles can push patients to ration — a medically dangerous practice.

This guide is a practical reference for providers and their care teams — covering what patients are actually paying, which programs exist, how to integrate cost conversations into your workflow, and what resources to have on hand.

What Are Patients Actually Paying for Tresiba?

Without insurance: $300–$500+ per box of FlexTouch pens; ~$444 for a 10 mL vial at full retail price.

With GoodRx: As low as $87–$122 depending on the pharmacy and specific formulation.

With SingleCare: Vial as low as $94 at participating pharmacies.

With commercial insurance: Varies widely. Tier 2-3 on most formularies. Some plans require step therapy (trial of insulin glargine first).

With Medicare Part D: $35/month maximum under the Inflation Reduction Act insulin cap (effective January 2025).

Program 1: Novo Nordisk Insulin Value Program

Available to both insured and uninsured patients. Eligible patients pay $35 for a monthly supply of any combination of Novo Nordisk insulin products — up to 3 vials or 2 packs of pens (up to 35 mL). This is the single most impactful affordability resource for most patients. Key details:

Available at NovoCare.com or call 1-888-668-6444

Applies to Tresiba U-100 and U-200 FlexTouch pens and vials

No income requirements for the Insulin Value Program (unlike the full PAP)

Available every month during the calendar year

Program 2: Medicare Part D $35/Month Insulin Cap

The Inflation Reduction Act capped insulin costs at $35/month for Medicare Part D enrollees, effective January 2025. Key points for your practice:

The cap applies to all covered insulin products, including Tresiba

It applies throughout all phases of coverage (including the deductible phase and coverage gap)

It is automatic — patients should not be charged more than $35/month for covered insulin

If a patient is being charged more, they should contact their plan directly or ask the pharmacist to reprocess the claim

Program 3: Manufacturer Savings Card (Commercial Insurance)

For commercially insured patients, the Novo Nordisk savings card can reduce their out-of-pocket cost to as little as $35 per 30-day prescription, with savings of up to $65 per fill. Patients whose copay exceeds $100 may pay no more than $99 per 35 mL prescription under an additional savings offer. Keep savings cards stocked in exam rooms and at your checkout desk.

Program 4: Novo Nordisk Patient Assistance Program (PAP)

For uninsured patients who cannot afford Tresiba even with the Insulin Value Program, the Novo Nordisk Patient Assistance Program provides Tresiba at no cost to qualified patients for up to one year. Income and residency requirements apply. Applications are at NovoCare.com or through a healthcare provider portal. Encourage eligible uninsured patients to apply.

Program 5: Prescription Discount Cards for Uninsured or Underinsured Patients

For patients who don't qualify for manufacturer programs or who have high-deductible plans, prescription discount cards can provide meaningful savings:

GoodRx: Shows pricing across pharmacies; can reduce Tresiba cost to as low as $87–$122.

SingleCare: Accepted at most major pharmacies; vial prices as low as $94.

RxSaver, InsideRx: Additional comparison tools that can offer competitive pricing at local pharmacies.

Important: Discount cards cannot be combined with insurance copays. They are most useful for uninsured patients or when the cash-price-with-coupon is lower than the insurance copay.

Integrating Cost Conversations Into Your Clinical Workflow

Cost rarely comes up unless you bring it up. Here's how to make it routine:

Ask about insurance before prescribing: "What kind of insurance do you have? Let's make sure Tresiba is covered before we send it."

Check formulary status proactively: If Tresiba requires prior authorization or step therapy, file the PA proactively so it's approved before the patient gets to the pharmacy.

Hand them a savings card at checkout: Keep Tresiba savings cards stocked. When prescribing Tresiba, hand the patient a card at the end of the visit.

Ask directly about affordability: "Have you had any trouble affording your insulin?" or "Are you taking it as prescribed, or have you been stretching doses?" Patients rarely volunteer this information unless asked.

Document cost-related switches: If you switch a patient to a less expensive alternative for affordability reasons, document why. This creates a paper trail for insurance appeals and ensures continuity across providers.

When Tresiba Is Also Hard to Find: Combining Affordability and Availability

During the 2025-2026 shortage, cost and availability are both challenges. Use medfinder for Providers to help patients locate pharmacies with Tresiba in stock — especially during supply constraints. Note in the patient's chart when they are having difficulty finding their medication, and provide an alternative insulin prescription as a bridge supply.

For a full clinical guide on managing the shortage, see: Tresiba Shortage: What Providers and Prescribers Need to Know in 2026.